Barbara-Jean Bormann-Kennedy Sells 16,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Barbara-Jean Bormann-Kennedy sold 16,000 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the transaction, the director directly owned 126,500 shares of the company’s stock, valued at $770,385. This trade represents a 11.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock traded up $0.03 during midday trading on Friday, hitting $6.18. 1,028,207 shares of the company traded hands, compared to its average volume of 1,829,779. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of 103.00 and a beta of 0.78. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The firm’s fifty day moving average price is $6.08 and its 200-day moving average price is $6.60. Xeris Biopharma Holdings, Inc. has a 12 month low of $4.30 and a 12 month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The business had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. As a group, sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on XERS. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday, March 2nd. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $10.80.

Institutional Investors Weigh In On Xeris Biopharma

Several large investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC bought a new stake in Xeris Biopharma in the fourth quarter worth approximately $25,000. KBC Group NV bought a new stake in Xeris Biopharma in the first quarter valued at $27,000. AlphaQuest LLC acquired a new position in shares of Xeris Biopharma during the third quarter valued at about $35,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after buying an additional 7,421 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after buying an additional 1,820 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.